SHS Gesellschaft für Beteiligungsmanagement mbH

What they fund

SHS Capital invests in healthcare companies with enterprise values up to 150 million EUR, with equity tickets typically ranging from 10 to 50 million EUR [1]. They target growth-stage companies, including SMEs and scale-ups, that demonstrate double-digit growth rates and seven-figure revenues [1]. The firm is flexible in its mandate, investing in both majority and minority positions [1]. Their geographic focus is primarily on the DACH region, Nordics, and Benelux, with selective investments in other European countries [1].

Investment thesis

SHS Capital invests in innovative, fast-growing healthcare companies to help them become European champions, leveraging over 30 years of sector-specific experience and a network of leading scientists, entrepreneurs, and investors [1]. The firm targets companies in growth situations, including SMEs and scale-ups, with a focus on market access, reimbursement, and M&A expertise to drive expansion [1]. They support both majority and minority investments in companies demonstrating double-digit growth and seven-figure revenues [1]. Credibility: The firm's own website outlines its mission, investment criteria, and value-add services, positioning itself as the leading German healthcare-dedicated private equity fund [1].

Value add

SHS Capital provides access to its extensive network of leading European scientists, entrepreneurs, and investors, developed over more than 30 years of experience in the healthcare sector [1]. The firm offers expertise in market access, reimbursement, marketing/sales, M&A, and exit strategies to support portfolio companies [1]. Fit verdict: SHS Capital is an ideal partner for healthcare companies seeking to scale across Europe with strategic guidance and network access. Founder diligence script: 1. How can SHS Capital's network specifically accelerate our market access strategy? 2. What is the typical timeline for SHS Capital to support a follow-on funding round? 3. How has SHS Capital facilitated M&A or exit opportunities for previous portfolio companies? 4. What specific expertise does SHS Capital bring to our sector within healthcare?

Portfolio focus

The firm has made over 75 investments since its founding in 1993, with a strong focus on healthcare and medical technology companies [1]. Their portfolio includes companies that have achieved significant growth and market leadership in Europe [1]. SHS Capital has facilitated over 50 successful exits, demonstrating a track record of value creation and strategic divestment [1].

Notable investments & exits

SHS Capital has facilitated over 50 successful exits since its founding in 1993, demonstrating a strong track record of value creation and strategic divestment [1]. The firm's expertise in M&A and exit strategies has been instrumental in helping portfolio companies achieve significant growth and market leadership [1]. Specific exit details are not provided in the available documents, but the firm's focus on healthcare and medical technology companies suggests a diverse portfolio of successful exits [1].

Strategic implications

SHS Capital's focus on the DACH region, Nordics, and Benelux positions it as a key player in the European healthcare investment landscape. The firm's expertise in market access and reimbursement is a significant differentiator, particularly for companies navigating complex regulatory environments. SHS Capital's track record of over 50 exits suggests a strong ability to identify and execute on value creation opportunities, making it an attractive partner for healthcare companies seeking to scale and exit.

Where they could go further

SHS Capital could expand its geographic focus to include other high-growth European healthcare markets, such as Southern Europe and Eastern Europe. The firm could enhance its value proposition by offering more structured support for early-stage companies, potentially through a dedicated pre-growth fund. SHS Capital could leverage its extensive network to facilitate more strategic partnerships and collaborations for its portfolio companies, driving additional value creation.